|
1
|
Fitzpatrick JM, Bellmunt J, Fizazi K,
Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda
S, Di Lorenzo G, et al: Optimal management of metastatic
castration-resistant prostate cancer: Highlights from a European
Expert Consensus Panel. Eur J Cancer. 50:1617–1627. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chi K, Hotte SJ, Joshua AM, North S, Wyatt
AW, Collins LL and Saad F: Treatment of mCRPC in the
AR-axis-targeted therapy-resistant state. Ann Oncol. 26:2044–2056.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Oudard S, Maroto P, Demonty G and
Gerritsen WR: Charting recent progress and challenges in metastatic
castration-resistant prostate cancer: Is there an optimal treatment
sequence? Eur Urol Focus. 2:426–440. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ingrosso G, Detti B, Scartoni D, Lancia A,
Giacomelli I, Baki M, Carta G, Livi L and Santoni R: Current
therapeutic options in metastatic castration-resistant prostate
cancer. Semin Oncol. 45:303–315. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Schalken J and Fitzpatrick JM:
Enzalutamide: Targeting the androgen signalling pathway in
metastatic castration-resistant prostate cancer. BJU Int.
117:215–225. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot
Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J,
Chowdhury S, et al: Enzalutamide in metastatic prostate cancer
before chemotherapy. N Engl J Med. 371:424–433. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Papazoglou D, Wannesson L, Berthold D,
Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R,
Barth A, Mingrone W, et al: Enzalutamide in patients with
castration-resistant prostate cancer progressing after docetaxel:
Retrospective analysis of the swiss enzalutamide named patient
program. Clin Genitourin Cancer. 15:e315–e323. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Miyake H, Hara T, Tamura K, Sugiyama T,
Furuse H, Ozono S and Fujisawa M: Comparative assessment of
efficacies between 2 alternative therapeutic sequences with novel
androgen receptor-axis-targeted agents in patients with
chemotherapy-naïve metastatic castration-resistant prostate cancer.
Clin Genitourin Cancer. 15:e591–e597. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Thiery-Vuillemin A, Poulsen MH, Lagneau E,
Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E,
Trepiakas R, Antoni L, et al: Impact of abiraterone acetate plus
prednisone or enzalutamide on fatigue and cognition in patients
with metastatic castration-resistant prostate cancer: Initial
results from the observational AQUARiUS study. ESMO Open.
3(e000397)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Khalaf DJ, Sunderland K, Eigl BJ,
Kollmannsberger CK, Ivanov N, Finch DL, Oja C, Vergidis J, Zulfiqar
M, Gleave ME and Chi KN: Health-related quality of life for
abiraterone plus prednisone versus enzalutamide in patients with
metastatic castration-resistant prostate cancer: Results from a
phase II randomized trial. Eur Urol. 75:940–947. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
de Bono JS, Chowdhury S, Feyerabend S,
Elliott T, Grande E, Melhem-Bertrandt A, Baron B, Hirmand M,
Werbrouck P and Fizazi K: Antitumour activity and safety of
enzalutamide in patients with metastatic castration-resistant
prostate cancer previously treated with abiraterone acetate plus
prednisone for ≥24 weeks in Europe. Eur Urol. 74:37–45.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ryan CJ, Smith MR, de Bono JS, Molina A,
Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng
S, et al: Abiraterone in metastatic prostate cancer without
previous chemotherapy. N Engl J Med. 368:138–148. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dearden L, Shalet N, Artenie C, Mills A,
Jackson C, Grant L and Gater A: Fatigue, treatment satisfaction and
health-related quality of life among patients receiving novel drugs
suppressing androgen signalling for the treatment of metastatic
castrate-resistant prostate cancer. Eur J Cancer Care (Engl).
28(e12949)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Roviello G and Generali D: Is the fatigue
an adverse event of the second generation of hormonal therapy? Data
from a literature-based meta-analysis. Med Oncol.
35(29)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Minton O, Richardson A, Sharpe M, Hotopf M
and Stone P: A systematic review and meta-analysis of the
pharmacological treatment of cancer-related fatigue. J Natl Cancer
Inst. 100:1155–1166. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yennurajalingam S, Frisbee-Hume S, Palmer
JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy
A, Hui D, et al: Reduction of cancer-related fatigue with
dexamethasone: A double-blind, randomized, placebo-controlled trial
in patients with advanced cancer. J Clin Oncol. 31:3076–3082.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Eguchi K, Honda M, Kataoka T, Mukouyama T,
Tsuneto S, Sakamoto J, Oba K and Saji S: Efficacy of
corticosteroids for cancer-related fatigue: A pilot randomized
placebo-controlled trial of advanced cancer patients. Palliat
Support Care. 13:1301–1308. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Langston B, Armes J, Levy A, Tidey E and
Ream E: The prevalence and severity of fatigue in men with prostate
cancer: A systematic review of the literature. Support Care Cancer.
21:1761–1771. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mitchell SA, Beck SL, Hood LE, Moore K and
Tanner ER: Putting evidence into practice: Evidence-based
interventions for fatigue during and following cancer and its
treatment. Clin J Oncol Nurs. 11:99–113. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nguyen DP, Li J and Tewari AK:
Inflammation and prostate cancer: The role of interleukin 6 (IL-6).
BJU Int. 113:986–992. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Miller AH, Ancoli-Israel S, Bower JE,
Capuron L and Irwin MR: Neuroendocrine-immune mechanisms of
behavioral comorbidities in patients with cancer. J Clin Oncol.
26:971–982. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schultz NM, Penson DF, Wilson S, Song Y,
Yang H, Ramaswamy K and Lowentritt B: Adverse events associated
with cumulative corticosteroid use in patients with
canstration-resistant prostate cancer: An administrative claims
analysis. Drug Saf. 43:23–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Miyake H, Hara T, Terakawa T, Ozono S and
Fujisawa M: Comparative assessment of clinical outcomes between
abiraterone acetate and enzalutamide in patients with
docetaxel-naive metastatic castration-resistant prostate cancer:
Experience in real-world clinical practice in Japan. Clin
Genitourin Cancer. 15:313–319. 2017.PubMed/NCBI View Article : Google Scholar
|
